11:23 AM EST, 03/08/2024 (MT Newswires) -- (Updates with Novo Nordisk's ( NVO ) response in the fifth paragraph and the latest stock movement in the sixth paragraph.)

Novo Nordisk ( NVO ) plans to offer the pill version of its experimental weight loss drug amycretin this decade, Reuters reported Friday, citing Martin Holst Lange, the company's head of development.

"I never commit to timelines, but I would be very comfortable to say at the very least within this decade," Lange said in an interview, according to the report.

More people will buy obesity drugs as prices drop over time, Reuters said in a separate report, citing Lars Fruergaard Jorgensen, Novo Nordisk's ( NVO ) chief executive officer.

"I expect that over time we'll see a lower price point that will cater for more and more patients getting on treatment," Jorgensen said in an interview, Reuters reported Friday. New generations of the medicine will justify price increases in select segments, he said, Reuters reported.

A Novo Nordisk ( NVO ) spokesperson confirmed Lange's interview with Reuters to MT Newswires.

Shares of the company fell over 2% in recent Friday trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 132.92, Change: -3.00, Percent Change: -2.21